Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmion Preps For MDS Competition; Vidaza Dosing Under Study

Executive Summary

Pharmion is testing more convenient dosing schedules for its myelodysplastic syndromes drug Vidaza (azacitidine) ahead of potential market entry of competitors in the fall

You may also be interested in...



MGI Dacogen Dosing Strategy Will Consider Reimbursement, Convenience

MGI Pharma is evaluating more convenient dosing strategies for its oncologic Dacogen in patients with myelodysplastic syndromes

Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder

Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel